Form D · Pharmaceuticals
Blue Rabbit Ventures, Inc.
Portland, ME · CIK 0001855180
Offering snapshot reported Jan 20, 2022 · SEC filing
- Reported sold
- $13.6M Offering amount: $26.6M
- Investors reported
- 16 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 16, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 20, 2022 | Initial | $13,636,055 | No comparison | 16 | SEC filing |
| Apr 8, 2021 | Initial | $14,547,174 | No comparison | 11 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-430083
Series B Preferred Stock
Source: Form D, filed Jan 20, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Marissa Bertorelli | Director |
| Edward L. Cahill | Director |
| Jon Lim | Director |
| Terrance G. Mc Guire | Director |
| Benjamin J. Shaw | Director, Executive, Promoter |
| Emily Snyder | Director |
| Bryce Youngren | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2 Union Street Suite 500
Portland, ME, 04101
Portland, ME, 04101